請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/51274
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李士傑 | |
dc.contributor.author | De-Fen Shih | en |
dc.contributor.author | 史德芬 | zh_TW |
dc.date.accessioned | 2021-06-15T13:29:10Z | - |
dc.date.available | 2016-03-08 | |
dc.date.copyright | 2016-03-08 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-02-04 | |
dc.identifier.citation | References
1. Christenson JG, Dairman W, Udenfriend S. On the identity of DOPA decarboxylase and 5-hydroxytryptophan decarboxylase (immunological titration-aromatic L-amino acid decarboxylase-serotonin-dopamine-norepinephrine). Proc Natl Acad Sci U S A. 1972;69(2):343-7. PubMed PMID: 4536745; PubMed Central PMCID: PMCPMC426454. 2. Crisp KM, Mesce KA. A cephalic projection neuron involved in locomotion is dye coupled to the dopaminergic neural network in the medicinal leech. J Exp Biol. 2004;207(Pt 26):4535-42. doi: 10.1242/jeb.01315. PubMed PMID: 15579549. 3. Kiehn O, Kjaerulff O. Spatiotemporal characteristics of 5-HT and dopamine-induced rhythmic hindlimb activity in the in vitro neonatal rat. J Neurophysiol. 1996;75(4):1472-82. PubMed PMID: 8727391. 4. Marder E, Eisen JS. Electrically coupled pacemaker neurons respond differently to same physiological inputs and neurotransmitters. J Neurophysiol. 1984;51(6):1362-74. PubMed PMID: 6145758. 5. Schotland J, Shupliakov O, Wikstrom M, Brodin L, Srinivasan M, You ZB, et al. Control of lamprey locomotor neurons by colocalized monoamine transmitters. Nature. 1995;374(6519):266-8. doi: 10.1038/374266a0. PubMed PMID: 7885446. 6. Verney C, Lebrand C, Gaspar P. Changing distribution of monoaminergic markers in the developing human cerebral cortex with special emphasis on the serotonin transporter. Anat Rec. 2002;267(2):87-93. doi: 10.1002/ar.10089. PubMed PMID: 11997877. 7. Gaspar P, Cases O, Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci. 2003;4(12):1002-12. doi: 10.1038/nrn1256. PubMed PMID: 14618156. 8. Holtz P, Heise, R., Lüdke, K. Fermentativer Abbau von l-Dioxyphenylalanin (Dopa) durch Niere. Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie. 1938;191(1):87-118. 9. Sumi-Ichinose C, Ichinose H, Takahashi E, Hori T, Nagatsu T. Molecular cloning of genomic DNA and chromosomal assignment of the gene for human aromatic L-amino acid decarboxylase, the enzyme for catecholamine and serotonin biosynthesis. Biochemistry. 1992;31(8):2229-38. PubMed PMID: 1540578. 10. Bruneau G, Gross MS, Krieger M, Bernheim A, Thibault J, Nguyen VC. Preparation of a human DOPA decarboxylase cDNA probe by PCR and its assignment to chromosome 7. Ann Genet. 1990;33(4):208-13. PubMed PMID: 1710430. 11. Swoboda KJ, Hyland K, Goldstein DS, Kuban KC, Arnold LA, Holmes CS, et al. Clinical and therapeutic observations in aromatic L-amino acid decarboxylase deficiency. Neurology. 1999;53(6):1205-11. PubMed PMID: 10522874. 12. Ichinose H, Kurosawa Y, Titani K, Fujita K, Nagatsu T. Isolation and characterization of a cDNA clone encoding human aromatic L-amino acid decarboxylase. Biochem Biophys Res Commun. 1989;164(3):1024-30. PubMed PMID: 2590185. 13. Lin YL, Gao J. Internal proton transfer in the external pyridoxal 5'-phosphate Schiff base in dopa decarboxylase. Biochemistry. 2010;49(1):84-94. doi: 10.1021/bi901790e. PubMed PMID: 19938875; PubMed Central PMCID: PMCPMC2827857. 14. Burkhard P, Dominici P, Borri-Voltattorni C, Jansonius JN, Malashkevich VN. Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase. Nat Struct Biol. 2001;8(11):963-7. doi: 10.1038/nsb1101-963. PubMed PMID: 11685243. 15. Giardina G, Montioli R, Gianni S, Cellini B, Paiardini A, Voltattorni CB, et al. Open conformation of human DOPA decarboxylase reveals the mechanism of PLP addition to Group II decarboxylases. Proc Natl Acad Sci U S A. 2011;108(51):20514-9. doi: 10.1073/pnas.1111456108. PubMed PMID: 22143761; PubMed Central PMCID: PMCPMC3251144. 16. Hahn SL, Hahn M, Joh TH. Genomic organization of the rat aromatic L-amino acid decarboxylase (AADC) locus: partial analysis reveals divergence from the Drosophila dopa decarboxylase (DDC) gene structure. Mamm Genome. 1991;1(3):145-51. PubMed PMID: 1797228. 17. Blechingberg J, Holm IE, Johansen MG, Borglum AD, Nielsen AL. Aromatic l-amino acid decarboxylase expression profiling and isoform detection in the developing porcine brain. Brain Res. 2010;1308:1-13. doi: 10.1016/j.brainres.2009.10.051. PubMed PMID: 19857468. 18. Panula P, Chen YC, Priyadarshini M, Kudo H, Semenova S, Sundvik M, et al. The comparative neuroanatomy and neurochemistry of zebrafish CNS systems of relevance to human neuropsychiatric diseases. Neurobiol Dis. 2010;40(1):46-57. doi: 10.1016/j.nbd.2010.05.010. PubMed PMID: 20472064. 19. McEwen BS, Olie JP. Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: tianeptine. Mol Psychiatry. 2005;10(6):525-37. doi: 10.1038/sj.mp.4001648. PubMed PMID: 15753957. 20. Bilsland JG, Wheeldon A, Mead A, Znamenskiy P, Almond S, Waters KA, et al. Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications. Neuropsychopharmacology. 2008;33(3):685-700. doi: 10.1038/sj.npp.1301446. PubMed PMID: 17487225. 21. Neff NH, Hadjiconstantinou M. Aromatic L-amino acid decarboxylase modulation and Parkinson's disease. Prog Brain Res. 1995;106:91-7. PubMed PMID: 8584678. 22. King JM, Muthian G, Mackey V, Smith M, Charlton C. L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease. Life Sci. 2011;89(17-18):638-43. doi: 10.1016/j.lfs.2011.08.008. PubMed PMID: 21871902; PubMed Central PMCID: PMCPMC3189304. 23. Brun L, Ngu LH, Keng WT, Ch'ng GS, Choy YS, Hwu WL, et al. Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. Neurology. 2010;75(1):64-71. doi: 10.1212/WNL.0b013e3181e620ae. PubMed PMID: 20505134. 24. Manegold C, Hoffmann GF, Degen I, Ikonomidou H, Knust A, Laass MW, et al. Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up. J Inherit Metab Dis. 2009;32(3):371-80. doi: 10.1007/s10545-009-1076-1. PubMed PMID: 19172410. 25. Lee HF, Tsai CR, Chi CS, Chang TM, Lee HJ. Aromatic L-amino acid decarboxylase deficiency in Taiwan. Eur J Paediatr Neurol. 2009;13(2):135-40. doi: 10.1016/j.ejpn.2008.03.008. PubMed PMID: 18567514. 26. Li Y, Li L, Stephens MJ, Zenner D, Murray KC, Winship IR, et al. Synthesis, transport, and metabolism of serotonin formed from exogenously applied 5-HTP after spinal cord injury in rats. J Neurophysiol. 2014;111(1):145-63. doi: 10.1152/jn.00508.2013. PubMed PMID: 24068759; PubMed Central PMCID: PMCPMC3921369. 27. Wienecke J, Ren LQ, Hultborn H, Chen M, Moller M, Zhang Y, et al. Spinal cord injury enables aromatic L-amino acid decarboxylase cells to synthesize monoamines. J Neurosci. 2014;34(36):11984-2000. doi: 10.1523/JNEUROSCI.3838-13.2014. PubMed PMID: 25186745. 28. Azam B, Wienecke J, Jensen DB, Azam A, Zhang M. Spinal Cord Hemisection Facilitates Aromatic L-Amino Acid Decarboxylase Cells to Produce Serotonin in the Subchronic but Not the Chronic Phase. Neural Plast. 2015;2015:549671. doi: 10.1155/2015/549671. PubMed PMID: 26504602; PubMed Central PMCID: PMCPMC4609486. 29. Papadopoulos EI, Petraki C, Gregorakis A, Chra E, Fragoulis EG, Scorilas A. L-DOPA decarboxylase mRNA levels provide high diagnostic accuracy and discrimination between clear cell and non-clear cell subtypes in renal cell carcinoma. Clin Biochem. 2015;48(9):590-5. doi: 10.1016/j.clinbiochem.2015.02.007. PubMed PMID: 25721989. 30. Wafa LA, Cheng H, Plaa N, Ghaidi F, Fukumoto T, Fazli L, et al. Carbidopa abrogates L-dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression. Int J Cancer. 2012;130(12):2835-44. doi: 10.1002/ijc.26287. PubMed PMID: 21780103. 31. Vachtenheim J, Novotna H. Expression of the aromatic L-amino acid decarboxylase mRNA in human tumour cell lines of neuroendocrine and neuroectodermal origin. Eur J Cancer. 1997;33(14):2411-7. PubMed PMID: 9616291. 32. Lai S, Wan Z. [Research of expression of L-DOPA decarboxylase in laryngeal cancer]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2014;28(24):1964-7, 71. PubMed PMID: 25895317. 33. Kontos CK, Papadopoulos IN, Fragoulis EG, Scorilas A. Quantitative expression analysis and prognostic significance of L-DOPA decarboxylase in colorectal adenocarcinoma. Br J Cancer. 2010;102(9):1384-90. doi: 10.1038/sj.bjc.6605654. PubMed PMID: 20424616; PubMed Central PMCID: PMCPMC2865762. 34. Vos MD, Scott FM, Iwai N, Treston AM. Expression in human lung cancer cell lines of genes of prohormone processing and the neuroendocrine phenotype. J Cell Biochem Suppl. 1996;24:257-68. PubMed PMID: 8806108. 35. Eaton MJ, Gudehithlu KP, Quach T, Silvia CP, Hadjiconstantinou M, Neff NH. Distribution of aromatic L-amino acid decarboxylase mRNA in mouse brain by in situ hybridization histology. J Comp Neurol. 1993;337(4):640-54. Epub 1993/11/22. doi: 10.1002/cne.903370409. PubMed PMID: 7904615. 36. Moreira-Rodrigues M, Sampaio-Maia B, Pestana M. Renal dopaminergic system activity in rat remnant kidney up to twenty-six weeks after surgery. Life Sci. 2009;84(13-14):409-14. doi: 10.1016/j.lfs.2008.12.018. PubMed PMID: 19167406. 37. Yang S, Yao B, Zhou Y, Yin H, Zhang MZ, Harris RC. Intrarenal dopamine modulates progressive angiotensin II-mediated renal injury. Am J Physiol Renal Physiol. 2012;302(6):F742-9. doi: 10.1152/ajprenal.00583.2011. PubMed PMID: 22169008; PubMed Central PMCID: PMCPMC3311314. 38. Eberling JL, Roberts JA, Taylor SE, VanBrocklin HF, O'Neil JP, Nordahl TE. No effect of age and estrogen on aromatic L- amino acid decarboxylase activity in rhesus monkey brain. Neurobiol Aging. 2002;23(3):479-83. PubMed PMID: 11959410. 39. Kitahama K, Ikemoto K, Jouvet A, Araneda S, Nagatsu I, Raynaud B, et al. Aromatic L-amino acid decarboxylase-immunoreactive structures in human midbrain, pons, and medulla. J Chem Neuroanat. 2009;38(2):130-40. doi: 10.1016/j.jchemneu.2009.06.010. PubMed PMID: 19589383. 40. Waymire JC, Gilmer-Waymire K. Adrenergic enzymes in cultured mouse neuroblastoma: absence of detectable aromatic-L-amino-acid decarboxylase. J Neurochem. 1978;31(3):693-8. Epub 1978/09/01. PubMed PMID: 28384. 41. Chatelin S, Wehrle R, Mercier P, Morello D, Sotelo C, Weber MJ. Neuronal promoter of human aromatic L-amino acid decarboxylase gene directs transgene expression to the adult floor plate and aminergic nuclei induced by the isthmus. Brain Res Mol Brain Res. 2001;97(2):149-60. PubMed PMID: 11750071. 42. Takezako T, Noda K, Tsuji E, Koga M, Sasaguri M, Arakawa K. Adenosine activates aromatic L-amino acid decarboxylase activity in the kidney and increases dopamine. J Am Soc Nephrol. 2001;12(1):29-36. PubMed PMID: 11134247. 43. Costa M, Furness JB, McLean JR. The presence of aromatic L-amino acid decarboxylase in certain intestinal nerve cells. Histochemistry. 1976;48(2):129-43. PubMed PMID: 955982. 44. Hayashi H, Mizuguchi H, Kagamiyama H. Rat liver aromatic L-amino acid decarboxylase: spectroscopic and kinetic analysis of the coenzyme and reaction intermediates. Biochemistry. 1993;32(3):812-8. PubMed PMID: 8422386. 45. Gilbert JA, Frederick LM, Ames MM. The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res. 2000;6(11):4365-72. Epub 2000/12/06. PubMed PMID: 11106255. 46. Kokkinou I, Nikolouzou E, Hatzimanolis A, Fragoulis EG, Vassilacopoulou D. Expression of enzymatically active L-DOPA decarboxylase in human peripheral leukocytes. Blood Cells Mol Dis. 2009;42(1):92-8. doi: 10.1016/j.bcmd.2008.10.010. PubMed PMID: 19041269. 47. Siow YL, Dakshinamurti K. Neuronal dopa decarboxylase. Ann N Y Acad Sci. 1990;585:173-88. PubMed PMID: 2192610. 48. Kuwabara H, Cumming P, Reith J, Leger G, Diksic M, Evans AC, et al. Human striatal L-dopa decarboxylase activity estimated in vivo using 6-[18F]fluoro-dopa and positron emission tomography: error analysis and application to normal subjects. J Cereb Blood Flow Metab. 1993;13(1):43-56. doi: 10.1038/jcbfm.1993.7. PubMed PMID: 8417009. 49. Wafa LA, Palmer J, Fazli L, Hurtado-Coll A, Bell RH, Nelson CC, et al. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. Hum Pathol. 2007;38(1):161-70. doi: 10.1016/j.humpath.2006.07.003. PubMed PMID: 16997353. 50. Arai R, Karasawa N, Geffard M, Nagatsu T, Nagatsu I. Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase. Brain Res. 1994;667(2):295-9. PubMed PMID: 7697371. 51. Alfadhel M, Kattan R. Aromatic amino Acid decarboxylase deficiency not responding to pyridoxine and bromocriptine therapy: case report and review of response to treatment. J Cent Nerv Syst Dis. 2014;6:1-5. doi: 10.4137/JCNSD.S12938. PubMed PMID: 24453523; PubMed Central PMCID: PMCPMC3891626. 52. Pons R, Ford B, Chiriboga CA, Clayton PT, Hinton V, Hyland K, et al. Aromatic L-amino acid decarboxylase deficiency: clinical features, treatment, and prognosis. Neurology. 2004;62(7):1058-65. PubMed PMID: 15079002. 53. Hyland K, Surtees RA, Rodeck C, Clayton PT. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesis. Neurology. 1992;42(10):1980-8. PubMed PMID: 1357595. 54. Atwal PS, Donti TR, Cardon AL, Bacino CA, Sun Q, Emrick L, et al. Aromatic L-amino acid decarboxylase deficiency diagnosed by clinical metabolomic profiling of plasma. Mol Genet Metab. 2015;115(2-3):91-4. doi: 10.1016/j.ymgme.2015.04.008. PubMed PMID: 25956449. 55. Hyland K, Clayton PT. Aromatic amino acid decarboxylase deficiency in twins. Journal of inherited metabolic disease. 1990;13(3):301-4. Epub 1990/01/01. PubMed PMID: 1700191. 56. Maller A, Hyland K, Milstien S, Biaggioni I, Butler IJ. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a second family. J Child Neurol. 1997;12(6):349-54. Epub 1997/10/06. PubMed PMID: 9309516. 57. Swoboda KJ, Saul JP, McKenna CE, Speller NB, Hyland K. Aromatic L-amino acid decarboxylase deficiency: overview of clinical features and outcomes. Ann Neurol. 2003;54 Suppl 6:S49-55. Epub 2003/08/02. doi: 10.1002/ana.10631. PubMed PMID: 12891654. 58. Manegold C, Hoffmann GF, Degen I, Ikonomidou H, Knust A, Laass MW, et al. Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up. Journal of inherited metabolic disease. 2009;32(3):371-80. Epub 2009/01/28. doi: 10.1007/s10545-009-1076-1. PubMed PMID: 19172410. 59. Lee WT, Weng WC, Peng SF, Tzen KY. Neuroimaging findings in children with paediatric neurotransmitter diseases. Journal of inherited metabolic disease. 2009;32(3):361-70. Epub 2009/05/21. doi: 10.1007/s10545-009-1106-z. PubMed PMID: 19455403. 60. Graziano C, Wischmeijer A, Pippucci T, Fusco C, Diquigiovanni C, Noukas M, et al. Syndromic intellectual disability: a new phenotype caused by an aromatic amino acid decarboxylase gene (DDC) variant. Gene. 2015;559(2):144-8. doi: 10.1016/j.gene.2015.01.026. PubMed PMID: 25597765. 61. Arnoux JB, Damaj L, Napuri S, Serre V, Hubert L, Cadoudal M, et al. Aromatic L-amino acid decarboxylase deficiency is a cause of long-fasting hypoglycemia. J Clin Endocrinol Metab. 2013;98(11):4279-84. doi: 10.1210/jc.2013-2740. PubMed PMID: 24037885. 62. Verbeek MM, Geurtz PB, Willemsen MA, Wevers RA. Aromatic L-amino acid decarboxylase enzyme activity in deficient patients and heterozygotes. Molecular genetics and metabolism. 2007;90(4):363-9. Epub 2007/01/24. doi: 10.1016/j.ymgme.2006.12.001. PubMed PMID: 17240182. 63. Ito S, Nakayama T, Ide S, Ito Y, Oguni H, Goto Y, et al. Aromatic L-amino acid decarboxylase deficiency associated with epilepsy mimicking non-epileptic involuntary movements. Dev Med Child Neurol. 2008;50(11):876-8. Epub 2008/08/30. doi: 10.1111/j.1469-8749.2008.03094.x. PubMed PMID: 18754761. 64. Zwagerman NT, Richardson RM. Gene therapy for aromatic L-amino acid decarboxylase deficiency. Neurosurgery. 2012;71(4):N10-2. doi: 10.1227/01.neu.0000419706.72039.5c. PubMed PMID: 22989964. 65. Haliloglu G, Vezir E, Baydar L, Onol S, Sivri S, Coskun T, et al. When do we need to perform a diagnostic lumbar puncture for neurometabolic diseases? Positive yield and retrospective analysis from a tertiary center. Turk J Pediatr. 2012;54(1):52-8. PubMed PMID: 22397043. 66. Chen PW, Lee NC, Chien YH, Wu JY, Wang PC, Hwu WL. Diagnosis of aromatic L-amino acid decarboxylase deficiency by measuring 3-O-methyldopa concentrations in dried blood spots. Clin Chim Acta. 2014;431:19-22. doi: 10.1016/j.cca.2014.01.034. PubMed PMID: 24513538. 67. Gucuyener K, Kasapkara CS, Tumer L, Verbeek MM. Aromatic L-Amino acid decarboxylase deficiency: A new case from Turkey with a novel mutation. Ann Indian Acad Neurol. 2014;17(2):234-6. doi: 10.4103/0972-2327.132652. PubMed PMID: 25024584; PubMed Central PMCID: PMCPMC4090859. 68. Tay SK, Poh KS, Hyland K, Pang YW, Ong HT, Low PS, et al. Unusually mild phenotype of AADC deficiency in 2 siblings. Mol Genet Metab. 2007;91(4):374-8. doi: 10.1016/j.ymgme.2007.04.006. PubMed PMID: 17533144. 69. Ichinose H, Sumi-Ichinose C, Ohye T, Hagino Y, Fujita K, Nagatsu T. Tissue-specific alternative splicing of the first exon generates two types of mRNAs in human aromatic L-amino acid decarboxylase. Biochemistry. 1992;31(46):11546-50. PubMed PMID: 1445888. 70. Chang YT, Mues G, Hyland K. Alternative splicing in the coding region of human aromatic L-amino acid decarboxylase mRNA. Neurosci Lett. 1996;202(3):157-60. PubMed PMID: 8848255. 71. Vassilacopoulou D, Sideris DC, Vassiliou AG, Fragoulis EG. Identification and characterization of a novel form of the human L-dopa decarboxylase mRNA. Neurochem Res. 2004;29(10):1817-23. PubMed PMID: 15532536. 72. Eberle ED, Eiduson S. Effect of pyridoxine deficiency on aromatic L-amino acid decarboxylase in the developing rat liver and brain. J Neurochem. 1968;15(10):1071-83. Epub 1968/10/01. PubMed PMID: 5711122. 73. Rahman MK, Nagatsu T, Sakurai T, Hori S, Abe M, Matsuda M. Effect of pyridoxal phosphate deficiency on aromatic L-amino acid decarboxylase activity with L-DOPA and L-5-hydroxytryptophan as substrates in rats. Jpn J Pharmacol. 1982;32(5):803-11. Epub 1982/10/01. PubMed PMID: 6983619. 74. Gaspar P, Cases O, Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci. 2003;4(12):1002-12. Epub 2003/11/18. doi: 10.1038/nrn1256. PubMed PMID: 14618156. 75. DeJesus OT, Flores LG, Roberts AD, Dick DW, Bartlett RM, Murali D, et al. Aromatic L-amino acid decarboxylase (AAAD) activity in rhesus macaque striatum after MAO-B inhibition by Ro 16-6491. Synapse. 2005;56(1):54-6. Epub 2005/02/09. doi: 10.1002/syn.20119. PubMed PMID: 15700282. 76. Yang S, Yao B, Zhou Y, Yin H, Zhang MZ, Harris RC. Intrarenal dopamine modulates progressive angiotensin II-mediated renal injury. Am J Physiol Renal Physiol. 2012;302(6):F742-9. Epub 2011/12/16. doi: 10.1152/ajprenal.00583.2011. PubMed PMID: 22169008; PubMed Central PMCID: PMC3311314. 77. Lee NC, Shieh YD, Chien YH, Tzen KY, Yu IS, Chen PW, et al. Regulation of the dopaminergic system in a murine model of aromatic L-amino acid decarboxylase deficiency. Neurobiol Dis. 2013;52:177-90. doi: 10.1016/j.nbd.2012.12.005. PubMed PMID: 23275025. 78. Lee NC, Muramatsu S, Chien YH, Liu WS, Wang WH, Cheng CH, et al. Benefits of Neuronal Preferential Systemic Gene Therapy for Neurotransmitter Deficiency. Mol Ther. 2015;23(10):1572-81. doi: 10.1038/mt.2015.122. PubMed PMID: 26137853. 79. Allen GF, Land JM, Heales SJ. A new perspective on the treatment of aromatic L-amino acid decarboxylase deficiency. Mol Genet Metab. 2009;97(1):6-14. doi: 10.1016/j.ymgme.2009.01.010. PubMed PMID: 19231266. 80. Fitzgerald P, Dinan TG. Prolactin and dopamine: what is the connection? A review article. J Psychopharmacol. 2008;22(2 Suppl):12-9. Epub 2008/08/16. doi: 22/2_suppl/12 [pii] 10.1177/0269216307087148. PubMed PMID: 18477617. 81. Swoboda KJ, Saul JP, McKenna CE, Speller NB, Hyland K. Aromatic L-amino acid decarboxylase deficiency: overview of clinical features and outcomes. Ann Neurol. 2003;54 Suppl 6:S49-55. doi: 10.1002/ana.10631. PubMed PMID: 12891654. 82. Korenke GC, Christen HJ, Hyland K, Hunneman DH, Hanefeld F. Aromatic L-amino acid decarboxylase deficiency: an extrapyramidal movement disorder with oculogyric crises. Eur J Paediatr Neurol. 1997;1(2-3):67-71. PubMed PMID: 10728198. 83. Chang YT, Sharma R, Marsh JL, McPherson JD, Bedell JA, Knust A, et al. Levodopa-responsive aromatic L-amino acid decarboxylase deficiency. Ann Neurol. 2004;55(3):435-8. doi: 10.1002/ana.20055. PubMed PMID: 14991824. 84. Ng J, Heales SJ, Kurian MA. Clinical features and pharmacotherapy of childhood monoamine neurotransmitter disorders. Paediatr Drugs. 2014;16(4):275-91. doi: 10.1007/s40272-014-0079-z. PubMed PMID: 25011953; PubMed Central PMCID: PMCPMC4102824. 85. Hwu WL, Muramatsu S, Tseng SH, Tzen KY, Lee NC, Chien YH, et al. Gene therapy for aromatic L-amino acid decarboxylase deficiency. Sci Transl Med. 2012;4(134):134ra61. doi: 10.1126/scitranslmed.3003640. PubMed PMID: 22593174. 86. Chtarto A, Bockstael O, Tshibangu T, Dewitte O, Levivier M, Tenenbaum L. A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting. Br J Clin Pharmacol. 2013;76(2):217-32. doi: 10.1111/bcp.12065. PubMed PMID: 23331189; PubMed Central PMCID: PMCPMC3731597. 87. Leuzzi V, Mastrangelo M, Polizzi A, Artiola C, van Kuilenburg AB, Carducci C, et al. Report of two never treated adult sisters with aromatic L-amino Acid decarboxylase deficiency: a portrait of the natural history of the disease or an expanding phenotype? JIMD Rep. 2015;15:39-45. doi: 10.1007/8904_2014_295. PubMed PMID: 24788355; PubMed Central PMCID: PMCPMC4270864. 88. Kari G, Rodeck U, Dicker AP. Zebrafish: an emerging model system for human disease and drug discovery. Clin Pharmacol Ther. 2007;82(1):70-80. Epub 2007/05/15. doi: 6100223 [pii] 10.1038/sj.clpt.6100223. PubMed PMID: 17495877. 89. Becker TS, Rinkwitz S. Zebrafish as a genomics model for human neurological and polygenic disorders. Dev Neurobiol. 2011. Epub 2011/04/06. doi: 10.1002/dneu.20888. PubMed PMID: 21465670. 90. Fleming A, Rubinsztein DC. Zebrafish as a model to understand autophagy and its role in neurological disease. Biochim Biophys Acta. 2011;1812(4):520-6. Epub 2011/01/25. doi: S0925-4439(11)00006-8 [pii] 10.1016/j.bbadis.2011.01.004. PubMed PMID: 21256213; PubMed Central PMCID: PMC3060341. 91. Newman M, Verdile G, Martins RN, Lardelli M. Zebrafish as a tool in Alzheimer's disease research. Biochim Biophys Acta. 2011;1812(3):346-52. Epub 2010/10/06. doi: S0925-4439(10)00212-7 [pii] 10.1016/j.bbadis.2010.09.012. PubMed PMID: 20920580. 92. Kabashi E, Brustein E, Champagne N, Drapeau P. Zebrafish models for the functional genomics of neurogenetic disorders. Biochim Biophys Acta. 2011;1812(3):335-45. Epub 2010/10/05. doi: S0925-4439(10)00211-5 [pii] 10.1016/j.bbadis.2010.09.011. PubMed PMID: 20887784. 93. Pienaar IS, Gotz J, Feany MB. Parkinson's disease: insights from non-traditional model organisms. Prog Neurobiol. 2010;92(4):558-71. Epub 2010/09/21. doi: S0301-0082(10)00159-0 [pii] 10.1016/j.pneurobio.2010.09.001. PubMed PMID: 20851733. 94. Bai Q, Burton EA. Zebrafish models of Tauopathy. Biochim Biophys Acta. 2011;1812(3):353-63. Epub 2010/09/21. doi: S0925-4439(10)00204-8 [pii] 10.1016/j.bbadis.2010.09.004. PubMed PMID: 20849952. 95. Teng Y, Xie X, Walker S, Rempala G, Kozlowski DJ, Mumm JS, et al. Knockdown of zebrafish Lgi1a results in abnormal development, brain defects and a seizure-like behavioral phenotype. Human molecular genetics. 2010;19(22):4409-20. Epub 2010/09/08. doi: ddq364 [pii] 10.1093/hmg/ddq364. PubMed PMID: 20819949; PubMed Central PMCID: PMC2957326. 96. Kabashi E, Champagne N, Brustein E, Drapeau P. In the swim of things: recent insights to neurogenetic disorders from zebrafish. Trends Genet. 2010;26(8):373-81. Epub 2010/06/29. doi: S0168-9525(10)00104-6 [pii] 10.1016/j.tig.2010.05.004. PubMed PMID: 20580116. 97. Hortopan GA, Dinday MT, Baraban SC. Zebrafish as a model for studying genetic aspects of epilepsy. Dis Model Mech. 2010;3(3-4):144-8. Epub 2010/03/10. doi: 3/3-4/144 [pii] 10.1242/dmm.002139. PubMed PMID: 20212082. 98. Sager JJ, Bai Q, Burton EA. Transgenic zebrafish models of neurodegenerative diseases. Brain Struct Funct. 2010;214(2-3):285-302. Epub 2010/02/18. doi: 10.1007/s00429-009-0237-1. PubMed PMID: 20162303. 99. Guo S. Using zebrafish to assess the impact of drugs on neural development and function. Expert Opin Drug Discov. 2009;4(7):715-26. Epub 2009/09/24. doi: 10.1517/17460440902988464. PubMed PMID: 19774094; PubMed Central PMCID: PMC2747263. 100. Hsu CH, Wen ZH, Lin CS, Chakraborty C. The zebrafish model: use in studying cellular mechanisms for a spectrum of clinical disease entities. Curr Neurovasc Res. 2007;4(2):111-20. Epub 2007/05/17. PubMed PMID: 17504209. 101. Huang YY, Rinner O, Hedinger P, Liu SC, Neuhauss SC. Oculomotor instabilities in zebrafish mutant belladonna: a behavioral model for congenital nystagmus caused by axonal misrouting. J Neurosci. 2006;26(39):9873-80. Epub 2006/09/29. doi: 26/39/9873 [pii] 10.1523/JNEUROSCI.2886-06.2006. PubMed PMID: 17005851. 102. Taylor MR, Hurley JB, Van Epps HA, Brockerhoff SE. A zebrafish model for pyruvate dehydrogenase deficiency: rescue of neurological dysfunction and embryonic lethality using a ketogenic diet. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(13):4584-9. Epub 2004/04/09. doi: 10.1073/pnas.0307074101. PubMed PMID: 15070761; PubMed Central PMCID: PMC384790. 103. Santana S, Rico EP, Burgos JS. Can zebrafish be used as animal model to study Alzheimer's disease? Am J Neurodegener Dis. 2012;1(1):32-48. PubMed PMID: 23383380; PubMed Central PMCID: PMCPMC3560447. 104. Mueller T, Vernier P, Wullimann MF. The adult central nervous cholinergic system of a neurogenetic model animal, the zebrafish Danio rerio. Brain Res. 2004;1011(2):156-69. doi: 10.1016/j.brainres.2004.02.073. PubMed PMID: 15157802. 105. Panula P, Sallinen V, Sundvik M, Kolehmainen J, Torkko V, Tiittula A, et al. Modulatory neurotransmitter systems and behavior: towards zebrafish models of neurodegenerative diseases. Zebrafish. 2006;3(2):235-47. doi: 10.1089/zeb.2006.3.235. PubMed PMID: 18248264. 106. Nowik N, Podlasz P, Jakimiuk A, Kasica N, Sienkiewicz W, Kaleczyc J. Zebrafish: an animal model for research in veterinary medicine. Pol J Vet Sci. 2015;18(3):663-74. doi: 10.1515/pjvs-2015-0086. PubMed PMID: 26618602. 107. Jiang F, Chen J, Ma X, Huang C, Zhu S, Wang F, et al. Analysis of mutants from a genetic screening reveals the control of intestine and liver development by many common genes in zebrafish. Biochem Biophys Res Commun. 2015;460(3):838-44. doi: 10.1016/j.bbrc.2015.03.119. PubMed PMID: 25824031. 108. Ota S, Kawahara A. Zebrafish: a model vertebrate suitable for the analysis of human genetic disorders. Congenit Anom (Kyoto). 2014;54(1):8-11. doi: 10.1111/cga.12040. PubMed PMID: 24279334. 109. Ekker SC, Larson JD. Morphant technology in model developmental systems. Genesis. 2001;30(3):89-93. Epub 2001/07/31. PubMed PMID: 11477681. 110. Barinaga M. Zebrafish: swimming into the development mainstream. Science. 1990;250(4977):34-5. Epub 1990/10/05. PubMed PMID: 2218513. 111. Muller UK, van Leeuwen JL. Swimming of larval zebrafish: ontogeny of body waves and implications for locomotory development. The Journal of experimental biology. 2004;207(Pt 5):853-68. Epub 2004/01/30. PubMed PMID: 14747416. 112. Yamamoto K, Ruuskanen JO, Wullimann MF, Vernier P. Two tyrosine hydroxylase genes in vertebrates New dopaminergic territories revealed in the zebrafish brain. Mol Cell Neurosci. 2010;43(4):394-402. Epub 2010/02/04. doi: 10.1016/j.mcn.2010.01.006. PubMed PMID: 20123022. 113. Yamamoto K, Ruuskanen JO, Wullimann MF, Vernier P. Differential expression of dopaminergic cell markers in the adult zebrafish forebrain. J Comp Neurol. 2011;519(3):576-98. Epub 2010/12/31. doi: 10.1002/cne.22535. PubMed PMID: 21192085. 114. Schweitzer J, Driever W. Development of the dopamine systems in zebrafish. Adv Exp Med Biol. 2009;651:1-14. Epub 2009/09/08. PubMed PMID: 19731546. 115. Holzschuh J, Ryu S, Aberger F, Driever W. Dopamine transporter expression distinguishes dopaminergic neurons from other catecholaminergic neurons in the developing zebrafish embryo. Mech Dev. 2001;101(1-2):237-43. Epub 2001/03/07. PubMed PMID: 11231083. 116. Rink E, Wullimann MF. The teleostean (zebrafish) dopaminergic system ascending to the subpallium (striatum) is located in the basal diencephalon (posterior tuberculum). Brain research. 2001;889(1-2):316-30. Epub 2001/02/13. PubMed PMID: 11166725. 117. Schweitzer J, Lohr H, Filippi A, Driever W. Dopaminergic and noradrenergic circuit development in zebrafish. Developmental neurobiology. 2012;72(3):256-68. Epub 2011/05/14. doi: 10.1002/dneu.20911. PubMed PMID: 21567980. 118. McLean DL, Fetcho JR. Ontogeny and innervation patterns of dopaminergic, noradrenergic, and serotonergic neurons in larval zebrafish. J Comp Neurol. 2004;480(1):38-56. doi: 10.1002/cne.20280. PubMed PMID: 15515022. 119. McLean DL, Fetcho JR. Relationship of tyrosine hydroxylase and serotonin immunoreactivity to sensorimotor circuitry in larval zebrafish. J Comp Neurol. 2004;480(1):57-71. doi: 10.1002/cne.20281. PubMed PMID: 15514919. 120. Thirumalai V, Cline HT. Endogenous dopamine suppresses initiation of swimming in prefeeding zebrafish larvae. J Neurophysiol. 2008;100(3):1635-48. doi: 10.1152/jn.90568.2008. PubMed PMID: 18562547; PubMed Central PMCID: PMCPMC2544474. 121. Whitlock KE, Westerfield M. The olfactory placodes of the zebrafish form by convergence of cellular fields at the edge of the neural plate. Development. 2000;127(17):3645-53. Epub 2000/08/10. PubMed PMID: 10934010. 122. Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF. Stages of embryonic development of the zebrafish. Dev Dyn. 1995;203(3):253-310. Epub 1995/07/01. doi: 10.1002/aja.1002030302. PubMed PMID: 8589427. 123. Thisse C, Thisse B. High-resolution in situ hybridization to whole-mount zebrafish embryos. Nat Protoc. 2008;3(1):59-69. Epub 2008/01/15. doi: 10.1038/nprot.2007.514. PubMed PMID: 18193022. 124. Minano FJ, McMillen BA, Myers RD. Central action of an inhibitor of brain dopa-decarboxylase, NSD-1015, on cyanamide-induced alcohol drinking in rats. Pharmacol Biochem Behav. 1990;35(2):465-8. Epub 1990/02/01. PubMed PMID: 2320657. 125. Hosseini-Sharifabad M, Nyengaard JR. Design-based estimation of neuronal number and individual neuronal volume in the rat hippocampus. J Neurosci Methods. 2007;162(1-2):206-14. Epub 2007/03/21. doi: 10.1016/j.jneumeth.2007.01.009. PubMed PMID: 17368561. 126. Chen Q, Huang NN, Huang JT, Chen S, Fan J, Li C, et al. Sodium benzoate exposure downregulates the expression of tyrosine hydroxylase and dopamine transporter in dopaminergic neurons in developing zebrafish. Birth Defects Res B Dev Reprod Toxicol. 2009;86(2):85-91. Epub 2009/03/19. doi: 10.1002/bdrb.20187. PubMed PMID: 19294673. 127. Korenke GC, Christen HJ, Hyland K, Hunneman DH, Hanefeld F. Aromatic L-amino acid decarboxylase deficiency: an extrapyramidal movement disorder with oculogyric crises. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. 1997;1(2-3):67-71. Epub 1997/01/01. PubMed PMID: 10728198. 128. Yang S, Lee YJ, Kim JM, Pa | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/51274 | - |
dc.description.abstract | 芳香族 L-氨基酸脫羧酶(AADC)缺乏症是一種罕見的兒童神經代謝性疾病。由於缺乏動物模型的參考,其致病機理目前所知甚少。本文主旨為產生AADC缺乏症的斑馬魚模型,以供未來研究AADC相關病理機制之用。原位雜交分析中顯示AADC基因在受精36小時後的斑馬魚胚胎中腦部的骨骺(epiphysis), 藍斑核(locus coeruleus), 間腦兒茶酚胺聚集(dipencephalic catecholaminergic clusters,DC), and 中縫核(raphe nuclei)有特別高的表現。使用AADC抑製劑NSD-1015或反股嗎 | zh_TW |
dc.description.abstract | Aromatic L-amino acid decarboxylase (AADC) deficiency is a rare pediatric neuro-metabolic disease in children. Due to the lack of an animal model, its pathogenetic mechanism is poorly understood. To study the role of AADC in brain development, a zebrafish model of AADC deficiency was generated. Whole-mount in situ hybridization analysis showed that the aadc gene was specifically expressed in the epiphysis, locus coeruleus, dipencephalic catecholaminergic (DC) clusters, and raphe nuclei of 36-h post-fertilization (hpf) zebrafish embryos. Inhibition of AADC by the inhibitor NSD-1015 or anti-sense morpholino (MO) led to a reduction brain volume and body length. There was an increased apoptosis occurrence in the brain and a loss of DC cluster neurons in AADC morphants (aadc MO-injected embryos). Seizure-like activity was also detected in AADC morphants in a dose-dependent manner. The AADC morphants were less sensitive in touch response and had a reduced swimming activity, and these phenotypes were rescued by injection of aadc plasmids. In conclusion, inhibition of AADC may reduce brain size, increase apoptosis, and reduce motor function in zebrafish. Zebrafish can be a useful model for investigating the pathogenetic mechanisms of AADC deficiency in children. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T13:29:10Z (GMT). No. of bitstreams: 1 ntu-105-D96B41007-1.pdf: 6861042 bytes, checksum: 91a1100868d38e35d33d48ba11ccecca (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | Contents
口試委員會審定書…………………………………………………………………….і Acknowledgement…………………………………………………...……………….ii Abstract (Chinese)…………………………………………………………………...ііі Abstract (English)……………………………………………………………………iv Abbreviations…………………………………………………………………………v List of figures…………………………………………………………………………vi List of tables…………………………………………………………………….….. vii 1. Introduction……………………………………………………………………...1 1.1 Aromatic Amino Acid Decarboxylase (AADC) ………………………....1 1.1.1 Morphology and Expression of AADC………………………………1 1.1.2 Function and Activity of AADC……………………………………...2 1.2 Aromatic Amino Acid Decarboxylase Deficiency………………………..5 1.2.1 Diagnosis, Clinical Features and Outcomes…………………………5 1.2.2 Previous Studies of AADC Deficiency……………………………….8 1.2.3 Therapy and Treatment of AADC Deficiency………………….……9 1.3 Zebrafish As Animal Model……………………………………………..13 1.3.1 Zebrafish As an Animal Model……………………………………..13 1.3.2 Catecholaminergic and Serotoninergic Neuron Development of Zebrafish …………………………………………………………….14 1.3.3 Motor Behaviors of Zebrafish………………………………………15 1.4 Goal for This Study………………………………………………………17 1.5 Publication Resulted from This Study……………………………….….17 2. Materials and Methods…………………………………………………………18 2.1 Ethics Statement .........................................................................................18 2.2 Fish strains and maintenance . ..................................................................18 2.3 Isolation and sequence analysis..................................................................18 2.4 RT-PCR analysis.........................................................................................19 2.5 Pharmacologic treatment to inhibit AADC activity.................................20 2.6 MO-mediated knockdown of ddc expression............................................20 2.7 AADC activity assay....................................................................................21 2.8 Electrophysiology of ddc knockdown fishs................................................22 2.9 ddc mRNA for rescue...................................................................................22 2.10 Whole Mount In situ hybridization...........................................................23 2.11 Evaluation of locomotor behavior .............................................................23 2.12 Analysis for eye movement.........................................................................24 2.13 Plastic section for brain structure analysis...............................................24 2.14 Immunohistochemical analysis..................................................................25 2.15 Appoptosis assay.........................................................................................26 2.16 Quantification and statistical analysis.......................................................26 3. Results...................................................................................................................27 3.1 Identification and expression of zebrafish ddc..........................................27 3.2 Inhibition or down-regulation of Ddc caused developmental and behavioral defects........................................................................................30 3.3 Loss of Ddc interfered DA neuron patterning...........................................34 3.4 Loss of Ddc caused seizure in zebrafish.....................................................35 3.5 Loss of Ddc impaired swimming activity...................................................36 3.6 Loss of DDC decreased eye movement.......................................................37 4. Discussion..............................................................................................................38 5. Summary...............................................................................................................46 6. References.............................................................................................................47 | |
dc.language.iso | en | |
dc.title | 芳香族 L-胺基酸脫羧酵素在腦發育與運動功能佔有重要角色 | zh_TW |
dc.title | Aromatic L-amino Acid Decarboxylase (AADC) is Crucial for Brain Development and Motor Functions | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 閔明源,郭典翰,蕭崇德,李旺祚 | |
dc.subject.keyword | AADC缺乏症,多巴胺,斑馬魚,嗎, | zh_TW |
dc.subject.keyword | AADC deficiency,dopamine,zebrafish,morpholino, | en |
dc.relation.page | 83 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2016-02-04 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生命科學系 | zh_TW |
顯示於系所單位: | 生命科學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 6.7 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。